title: [Grapefruit juice as a contraindication? An approach in psychiatry].
abstract: The authors investigated in this preliminary study the influence of grapefruit juice on the metabolism of two tricyclic antidepressants. An increase of plasma concentrations is observed indeed for many drugs when administered concomitantly with grapefruit juice. This effect was mainly attributed to inhibition of cytochrome P450 1A2 and 3A4 enzymes by naringenin. These isoenzymes are involved too in the metabolism of many psychotropic drugs. Only two benzodiazepines (midazolam and triazolam) were studied in the conditions of grapefruit juice association. All these studies are performed in healthy subjects and with a study design very different from the clinical conditions. On the basis of these considerations, the authors hypothesized that grapefruit juice should inhibit tricyclic antidepressant metabolism and thus increase the bioavailability of these drugs. They want to precise if this possible drug plasma level increase could be clinically important for depressed patients. Fourteen depressed inpatients were selected for the study. Seven of them received amitriptyline (100 to 150 mg/d) and the seven others clomipramine (112.5 to 225 mg/d). Tricyclic antidepressant and desmethylated metabolite plasma levels were determined on four occasions. The first and second day samples were obtained to determined the plasma level intraindividual variability of antidepressants. On the third and fourth days, plasma levels were determined after an oral coadministration of the antidepressant and 250 ml of pure and fresh grapefruit juice. One patient was excluded from the study due to the coadministration of clomipramine and fluvoxamine. There is indeed a major drug-interaction between these two drugs, and the tricyclic antidepressant plasma levels of this patient were in the toxic range, without side effect. In this group of patients, there was no metabolic interaction between amitriptyline and grapefruit juice. But the mean plasma levels of clomipramine and desmethylclomipramine increased after coadministration of this juice (+4.5% and +10.5% respectively). The authors concluded that with these preliminary results, the potential clinical relevance of this interaction cannot be estimated.
authors: Service de Psychiatrie et Psychologie Médicale, CHU, Besançon.
authors: P
authors: P
authors: Vandel
authors: W
authors: W
authors: Regina
authors: I
authors: I
authors: Reix
authors: S
authors: S
authors: Vandel
authors: D
authors: D
authors: Sechter
authors: P
authors: P
authors: Bizouard
mesh_terms: D000328:Adult; D000368:Aged; D000639:Amitriptyline / Q000097:blood / Q000493:pharmacokinetics* / Q000627:therapeutic use; D000929:Antidepressive Agents, Tricyclic / Q000097:blood / Q000493:pharmacokinetics* / Q000627:therapeutic use; D001628:Beverages; D002957:Citrus / Q000009:adverse effects*; D002997:Clomipramine / Q000097:blood / Q000493:pharmacokinetics* / Q000627:therapeutic use; D003577:Cytochrome P-450 Enzyme System / Q000378:metabolism; D003866:Depressive Disorder / Q000188:drug therapy; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged
chemical_list: D000929:Antidepressive Agents, Tricyclic; D000639:Amitriptyline; D003577:Cytochrome P-450 Enzyme System; D002997:Clomipramine